Plain Language Summary of Publication: Design of the Phase 3 AZALEA Trial of Nipocalimab in Severe Hemolytic Disease of the Fetus and Newborn
American Journal of Perinatology · 01.05.2025 · 42 (07) · 955-961
DOI: 10.1055/a-2529-4150 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Perinatology, erschienen am 01.05.2025. Verfasst von Yosuke Komatsu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Janssen Pharmaceutical Companies of Johnson & Johnson, Cambridge, Massachusetts. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Erythroblastosis, Fetal. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Janssen Research & Development, LLC, a Johnson & Johnson Company, Panita Trenor, PhD, of Lumanity Communications Inc., Janssen Global Services, LLC, a Johnson & Johnson Company.
Abstract (Originalsprache)
This article is a plain language summary of publication (PLSP) of the following article: Design of a phase 3, global, multicenter, randomized, placebo-controlled, double-blind study of nipocalimab in pregnancies at risk for severe hemolytic disease of the fetus and newborn by Komatsu et al published in American Journal of Perinatology on September 17, 2024 (doi:10.1055/a-2404-8089). This PLSP describes the design of the phase 3 AZALEA clinical trial in pregnant participants at risk for developing severe hemolytic disease of the fetus and newborn (HDFN). In this study, researchers will determine if an investigational treatment called nipocalimab can be used safely and effectively to treat pregnant individuals who are at risk for severe HDFN. This PLSP will help members of the public, including individuals and families affected by HDFN, understand the study. It may also be helpful for health care professionals. An infographic summary of this article is available in the Supplementary Material.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Janssen Pharmaceutical Companies of Johnson & Johnson, Cambridge, Massachusetts.
- Dell Medical School, The University of Texas at Austin, Austin, Texas.
- Comprehensive Fetal Care Center at Dell Children's Medical Center, Austin, Texas.
ORCID-Profile: Kenneth J Moise
Förderung
- Janssen Research & Development, LLC, a Johnson & Johnson Company
- Panita Trenor, PhD, of Lumanity Communications Inc.
- Janssen Global Services, LLC, a Johnson & Johnson Company
Zitieren
APA
Komatsu, Y., Olusajo, V., Ling, L. E., Saeed-Khawaja, S., Tjoa, M. L., Vaikunthanathan, T., Mirza, A., & Moise, K. J. (2025). Plain Language Summary of Publication: Design of the Phase 3 AZALEA Trial of Nipocalimab in Severe Hemolytic Disease of the Fetus and Newborn. American Journal of Perinatology, 42(07), 955-961. https://doi.org/10.1055/a-2529-4150
Vancouver
Komatsu Y, Olusajo V, Ling LE, Saeed-Khawaja S, Tjoa ML, Vaikunthanathan T, et al. Plain Language Summary of Publication: Design of the Phase 3 AZALEA Trial of Nipocalimab in Severe Hemolytic Disease of the Fetus and Newborn. American Journal of Perinatology. 2025;42(07):955-961. doi:10.1055/a-2529-4150
BibTeX
@article{Komatsu2025,
author = {Komatsu, Yosuke and Olusajo, Victor and Ling, Leona E and Saeed-Khawaja, Shumyla and Tjoa, May Lee and Vaikunthanathan, Trishan and Mirza, Arpana and Moise, Kenneth J},
title = {Plain Language Summary of Publication: Design of the Phase 3 AZALEA Trial of Nipocalimab in Severe Hemolytic Disease of the Fetus and Newborn},
journal = {American Journal of Perinatology},
year = {2025},
volume = {42},
number = {07},
pages = {955--961},
doi = {10.1055/a-2529-4150}
}
EUVIMED